Cynata-logo.png
Cynata’s Cymerus™ MSCs Effective in Preclinical Model of Diabetic Wounds
01 juin 2018 08h00 HE | Cynata Therapeutics Limited
MELBOURNE, Australia, June 01, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that it has received...
Cynata-logo.png
$5.2m placement of shares to Fidelity International
30 mai 2018 09h31 HE | Cynata Therapeutics Limited
MELBOURNE, Australia, May 30, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) (‘Cynata’) is pleased to announce a A$5.2 million...
Cynata-logo.png
Enrolment Completed in Cynata’s Phase 1 Clinical Trial of CYP-001 in GvHD
24 mai 2018 08h00 HE | Cynata Therapeutics Limited
MELBOURNE, Australia, May 24, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the final patient has...
Cynata-logo.png
Cynata Therapeutics Completes Patent Application to Cover Cymerus™ Stem Cell Technology in the Treatment of Side Effects Related to CAR-T Therapy
20 avr. 2018 07h00 HE | Cynata Therapeutics Limited
Initial data from preclinical study at the University of Massachusetts Amherst demonstrate Cymerus MSCs ameliorate the effects of cytokine release syndrome (CRS) and other related adverse reactions to...
Cynata-logo.png
Cynata to Present at the Preeminent Cell & Gene Therapy Investor Day in New York
12 avr. 2018 13h04 HE | Cynata Therapeutics Limited
MELBOURNE, Australia, April 12, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to announce that it has been...
Cynata-logo.png
FDA Grants Orphan Drug Designation to Cynata’s Lead Cymerus™ MSC Product, CYP-001
28 mars 2018 08h00 HE | Cynata Therapeutics Limited
MELBOURNE, Australia, March 28, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the United States...
Cynata-logo.png
Excellent Cohort A Data From Final Primary Evaluation Period in Cynata GvHD Phase 1 Clinical Trial
27 févr. 2018 08h00 HE | Cynata Therapeutics Limited
MELBOURNE, Australia, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the Primary...
Cynata-logo.png
Treatment Commences in Second Patient Cohort in Cynata’s World First Clinical Trial
24 janv. 2018 08h00 HE | Cynata Therapeutics Limited
MELBOURNE, Australia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to announce that the first patient...
Cynata-logo.png
Cynata Executes MoU for Commercial Evaluation with Celularity, Inc.
23 janv. 2018 10h05 HE | Cynata Therapeutics Limited
MoU signed with Celularity, Inc. for the evaluation of and identification of commercial opportunities for the CymerusTM platform and Celularity’s leading cell therapy assetsFollows...
Cynata-logo.png
Encouraging Early Safety and Efficacy Data in Cynata’s Phase 1 Trial of CYP-001 in GvHD; DSMB Recommendation to Initiate Enrolment of Second Patient Cohort
22 janv. 2018 08h00 HE | Cynata Therapeutics Limited
MELBOURNE, Australia, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the independent Data...